Search

In 2022, the National Cancer Center released the latest data. The results show that the incidence of gynecologic tumors in China shows an upward trend. Taking ovarian cancer as an example, the annual number of new cases is 57 200, with a crude incidence rate of 8.47/100 000, and the annual number of death cases is 27 200, with a crude mortality rate of 4.04/100 000, and the morbidity and mortality are higher than the world standard rates (5.59/100 000 and 2.45/100 000, respectively). Physicians practicing gynecologic oncology in China face greater challenges. Patients with early gynecologic tumors have better overall outcomes after standardized treatment. However, limited treatment modalities and high recurrence rates often lead to poorer prognosis for patients with advanced, recurrent or metastatic gynecologic malignancies. In recent years, emerging treatments such as targeted therapy, immunotherapy and antibody-drug conjugate have ushered in a new era in the treatment of gynecologic tumors, bringing more hope to patients. This article summarized the significant advances in gynecological tumor surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and biomarkers in the past year, so as to better guide the individualized and precise treatment of gynecologic tumors. [ABSTRACT FROM AUTHOR]

Combined with the expression profile of long non-coding RNA (IncRNA) and somatic mutation profile in the genome of cervical cancer in TCGA database, a computational framework based on mutation hypothesis was established. A total of 36 IncRNAs associated with genomic instability of cervical cancer were identified, and the function of their co-expressed genes was analyzed. The genes co-expressed with 36 IncRNAs were enriched in the 2-oxy-glutarate and 2-oxy-carboxylic acid metabolic pathways. Gene signatures (GILncSig) of two IncRNAs derived from genomic instability were determined, and the Train group was divided into a high-risk group and a low-risk group. The survival rates of the two groups were significantly different, which was further validated in the Test cohort. According to independent prognostic analysis, GILncSig was an independent prognostic factor associated with overall survival of cervical cancer patients. In conclusion, this study provides key methods and resources to further investigate the role of IncRNA in genomic instability, and provides a potential new pathway for identifying cancer biomarkers associated with genomic instability. [ABSTRACT FROM AUTHOR]